Shijiazhuang Yiling Pharmaceutical (002603.SZ): Withdrawal of the application for clinical trials of "G201-Na Capsules" medication.
Lingyun Pharmaceuticals (002603.SZ) announced that the company will follow the relevant drug approval policies and combine them with the progress of its research projects...
Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that, based on the relevant policies of drug approval and the progress of research projects, the company has decided, after careful consideration, to apply to the National Medical Products Administration (hereinafter referred to as "NMPA") to withdraw the clinical trial application for the drug "G201-Na Capsules" for the indication of "assisted reproduction". Recently, the company received the "Notice of Termination of Drug Registration Application" issued by the NMPA.
Related Articles
Shougang Cent (00103) intends to appoint Ernst & Young as its auditor.
TVB(00511): Xu Jing will transfer his ownership rights of YLH shares to the Chairman of the Board of Directors, Xu Tao.
SHIMAO GROUP (00813) accumulated contract sales totaled approximately RMB 9.07 billion in the first four months.
Shougang Cent (00103) intends to appoint Ernst & Young as its auditor.
TVB(00511): Xu Jing will transfer his ownership rights of YLH shares to the Chairman of the Board of Directors, Xu Tao.
SHIMAO GROUP (00813) accumulated contract sales totaled approximately RMB 9.07 billion in the first four months.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
